Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 0.52 |
| ▸ | FNTB | P49356 | 20/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 19/20 | 0.52 |
| ▸ | NRAS | P01111 | 1/20 | 0.48 |
| ▸ | HRAS | P01112 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7588984 | 0.84 | FNTA (0.51) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL7543890 | 0.83 | FNTA (0.51) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7593579 | 0.83 | FNTA (0.50) | FNTAFNTBPGGT1BNRASHRAS | |
| Hydrochloric Acid SCHEMBL7541542 | 0.78 | FNTA (0.53) | FNTAFNTBPGGT1BNRASHRAS | |
| SCHEMBL7159262 | 0.75 | FNTA (0.67) | FNTAFNTBPGGT1B | |
| SCHEMBL7665146 | 0.74 | FNTA (0.73) | FNTAFNTBPGGT1B | |
| SCHEMBL7589813 | 0.73 | FNTA (0.66) | FNTAFNTBPGGT1B | |
| SCHEMBL7483969 | 0.73 | FNTA (0.69) | FNTAFNTBPGGT1B | |
| SCHEMBL7593586 | 0.73 | FNTA (0.55) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL7593674 | 0.72 | FNTA (0.60) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | claimed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | claimed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | disclosed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | GGT1, FNTA, GGPS1 | FNTA 2/4885FNTB 7/4885PGGT1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.